Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIRMID Trial: Nebulized Matrix (HAF) in Interstitial Lung Disease
NCT07372989Phase 1Recruiting
- Sponsor
- Maule Stem Cell Research Institute
- Start
- Feb 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial in interstitial lung disease (ILD) (2 cohorts), sponsored by Maule Stem Cell Research Institute. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 13 months. Started Feb 2026; status: recruiting.
02
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07372989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07372989.